The significance of IL-1 in atherosclerosis was demonstrated in the CANTOS trial, where treatment with canakinumab, a monoclonal antibody targeting IL-1, reduced the primary endpoint of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death [299]. The gene discussed is IL1B; the disease is myocardial infarction.